BioCentury
ARTICLE | Finance

3Q Financial Markets Preview: Hoping the rally has legs

Buysiders hope public biotechs will resurge in 2H11 after outperforming in 1H11

July 4, 2011 7:00 AM UTC

Buysiders expect biotech may be able to continue to outperform the broader markets, despite a retreat from spring highs. In particular, they see two bright spots for the sector: selective gains on a full calendar of clinical and regulatory events and continued financings by late-stage companies.

Phase III companies have had no trouble raising enough cash to make it well into the launch phase, evidenced by a flurry of large follow-ons not seen since 2009...